Aqualung Therapeutics is a biotechnology company focused on developing innovative treatments for serious inflammatory disorders. The company's core product is a novel anti-inflammatory monoclonal antibody designed to target and mitigate severe inflammation. Aqualung Therapeutics operates in the biopharmaceutical market, primarily serving healthcare providers and patients affected by conditions such as COVID-19, prostate cancer, and radiation-induced lung injury. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary biologic therapies. Revenue is generated through funding rounds, partnerships, and future sales of approved treatments. The company is currently seeking $15 million in Series A funding to advance the manufacturing of its lead drug candidate.

Keywords: biotechnology, anti-inflammatory, monoclonal antibody, inflammatory disorders, COVID-19, prostate cancer, lung injury, healthcare, biopharmaceutical, clinical trials.